Fourteen years later: Reviewing the diagnostic criteria for behavioral‐variant frontotemporal dementia
Year: 2025
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: Diagnosis of behavioral-variant frontotemporal dementia (bvFTD) requires the presence of at least three of six core features. The contribution of each criterion toward diagnosis, however, remains unclear. We aimed to determine the frequency and combinations of diagnostic criteria at presentation and their contribution to survival. METHODS: Consecutive patients with a stable diagnosis of bvFTD between 2010 and 2023 were included. Demographic and cognitive data were also collected. RESULTS: A total of 110 patients were identified. Frequency of diagnostic criteria ranged from 89% (apathy; empathy loss) to 14.5% (dysexecutive profile), and 78 patients met at least four criteria. Mean survival time from symptom onset was 10.4 years and was not affected by the number and combination of core diagnostic criteria (P values ≥ 0.274). DISCUSSION: Our findings show that the requirements for the cognitive criterion are disproportionately restrictive, which may delay diagnosis and access to relevant treatments and therapies. HIGHLIGHTS: The comparative usefulness of core criteria for frontotemporal dementia diagnosis is unclear. We identified the most common profiles of core features at baseline. Most common feature profiles included apathy and/or empathy loss. Feature profiles were not predictive of survival. Cognitive criterion appears overly restrictive in its current form.
Source: Alzheimer s & Dementia
DOI: 10.1002/alz.70604
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,200
Awards: Maximising quality of life in frontotemporal dementia, Functional connectivity-guided transcranial magnetic stimulation (TMS) treatment for young people with major depression, G3243364414, Discovery of novel neurodegeneration genes via next-generation sequencing technologies and high-throughput cellular assays, G5010192015, Towards treatments for non-Alzheimer neurodegenerative diseases by establishing their biology from presymptomatic to terminal stages, G8135170174, Frontotemporal dementia and motor neurodegenerative syndromes
OpenAlex ID: W4413299541
